[Use of small-dose Cyclosporine HEXAL in the treatment of postoperative inflammation during intraocular surgical reinterventions].
The effectiveness of small doses of the selective immunosuppressive agent Cyclosporine HEXAL (2-2.5 mg/kg) was studied in 112 patients with early inflammatory reactions developing after various surgical reinterventions (cataract phacoemulsification with intraocular lens implantation after antiglaucoma surgery, repeated antiglaucoma, reconstructive operations, etc.). The drug was given as a short course for 5-10 days. As compared to the conventional treatment with corticosteroids and nonsteroidal anti-inflammatory drugs (NSAID), Cyclosporine HEXAL exerted a rapider therapeutic effect, reducing the duration of exudate resolution and corneal edema and the length of hospital stay and improving functional outcomes. The drug was found to be well tolerated and induced adverse reactions in sporadic cases. Cyclosporine HEXAL may be recommended as the drug of choice in the treatment of the severest postoperative uveitis, particularly if there are contraindications to systemic and long-term use of corticosteroids and NSAID.
Levanova
O G
OG
Arkhipova
L T
LT
D016572:Cyclosporine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D009877:Endophthalmitis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007430:Intraoperative Care / Q000379:methods*; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects*; D011183:Postoperative Complications; D012086:Reoperation / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine